News
ELTX
2.180
-7.23%
-0.170
Weekly Report: what happened at ELTX last week (0831-0904)?
Weekly Report · 2d ago
Weekly Report: what happened at ELTX last week (0824-0828)?
Weekly Report · 08/31 09:54
Weekly Report: what happened at ELTX last week (0817-0821)?
Weekly Report · 08/24 09:54
Analysts Offer Insights on Healthcare Companies: Obsidian Therapeutics (OBX), Elicio Therapeutics (ELTX) and Aethlon Medical (AEMD)
TipRanks · 08/18 10:30
Analysts Offer Insights on Healthcare Companies: Elicio Therapeutics (ELTX), EyePoint Pharmaceuticals (EYPT) and LeonaBio (LONA)
TipRanks · 08/17 12:30
Weekly Report: what happened at ELTX last week (0810-0814)?
Weekly Report · 08/17 09:55
Elicio Therapeutics GAAP EPS of -$0.43 beats by $0.11
Seeking Alpha · 08/13 20:53
Press Release: Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Dow Jones · 08/13 20:01
Elicio Therapeutics: Q2 Earnings Snapshot
Barchart · 08/13 15:26
Weekly Report: what happened at ELTX last week (0803-0807)?
Weekly Report · 08/10 09:52
Weekly Report: what happened at ELTX last week (0727-0731)?
Weekly Report · 08/03 09:51
Weekly Report: what happened at ELTX last week (0720-0724)?
Weekly Report · 07/27 09:54
Weekly Report: what happened at ELTX last week (0713-0717)?
Weekly Report · 07/20 09:52
Weekly Report: what happened at ELTX last week (0706-0710)?
Weekly Report · 07/13 09:53
Largest borrow rate increases among liquid names
TipRanks · 07/09 12:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 07/08 17:05
Largest borrow rate increases among liquid names
TipRanks · 07/07 12:45
Weekly Report: what happened at ELTX last week (0629-0703)?
Weekly Report · 07/06 09:56
11 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 07/02 17:05
More
Webull provides a variety of real-time ELTX stock news. You can receive the latest news about Elicio Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.